Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules

Janine Dilchert1,2, Martin Hofmann1, Felix Unverdorben1

  • 1Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tuebingen, Germany.

Insights

Chinese Hamster Ovary (CHO) display enables affinity maturation of bispecific T cell engaging receptor (TCER) molecules. This novel system improves T cell redirection for cancer therapy by enhancing T cell receptor (TCR) affinity and stability.

Area of Science:

  • Biotechnology
  • Immunotherapy
  • Oncology

Background:

  • Bispecific T cell receptor (TCR)-based molecules are promising cancer biotherapeutics.
  • TCRs target intracellular antigens but require affinity and stability maturation.
  • Existing maturation methods have limitations like non-human glycosylation and reformatting needs.

Purpose of the Study:

  • To develop and apply a Chinese Hamster Ovary (CHO) display system for affinity engineering of TCRs.
  • To mature bispecific T cell engaging receptor (TCER) molecules within their final format.
  • To enhance TCR affinity and stability for improved cancer targeting.

Main Methods:

  • Utilized a recombinase-mediated cassette exchange (RCME) system for stable, single-copy integration of bispecific TCR molecules in CHO cells.
  • Developed a CHO display platform for affinity maturation of TCRs.
  • Generated and screened a library of CDR variants of a PRAME-targeting TCR.

Main Results:

  • Successfully developed and applied a CHO display system for TCR affinity maturation.
  • Isolated affinity-increased TCER variants targeting PRAME.
  • Selected TCER molecules showed strong reactivity against PRAME-positive tumor cells and induced significant cytokine release.

Conclusions:

  • The CHO display system is effective for TCR affinity maturation in the context of the final bispecific TCER format.
  • This platform facilitates the development of enhanced biotherapeutics for cancer treatment.
  • The developed TCER molecules demonstrate potential for effective cancer immunotherapy.